The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
| Factor | Score | Distribution | Value | Avg | Verdict |
|---|---|---|---|---|---|
Valuation | 47 | 14.0x | 20.1x | Near average | |
Growth | 87 | 30.2% | 5.6% | Above average | |
Quality | 53 | -518.0% | 7.6% | Near average | |
Safety | 77 | -3.8x | 0.4x | Above average | |
Capital Return | 20 | 0.00% | 2.19% | Below average | |
Momentum | — | — | — | No data | |
Sentiment | — | — | — | No data |
TransMedics Group, Inc. is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.
You can buy TransMedics Group, Inc. shares through a licensed brokerage. Research the company's financials before investing.
Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.
Dividend policies vary by company. Check the dividends section on the stock page for the payout history.
Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.
AI analysis from the earnings call, financials and news
This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.
TransMedics stock has seen a gradual decline in the average price target by 3.32% over the past thirty days, as the consensus dropped from 124.33 to 120.2 dollars. Despite this slight downward adjustment, the average price target remains significantly higher than the current price (68.45 dollars), indicating a wide valuation gap that reflects future optimism tempered by near-term caution.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.